Sintx Technologies, Inc. (NASDAQ:SINT) Short Interest Up 20.3% in December

Sintx Technologies, Inc. (NASDAQ:SINT) was the target of a large increase in short interest in December. As of December 31st, there was short interest totaling 206,724 shares, an increase of 20.3% from the December 15th total of 171,790 shares. Approximately 5.8% of the shares of the stock are sold short. Based on an average daily volume of 40,662 shares, the days-to-cover ratio is presently 5.1 days. Based on an average daily volume of 40,662 shares, the days-to-cover ratio is presently 5.1 days. Approximately 5.8% of the shares of the stock are sold short.

Insider Activity at Sintx Technologies

In related news, CIO Gregg R. Honigblum acquired 65,000 shares of the company’s stock in a transaction on Friday, December 5th. The stock was acquired at an average price of $3.93 per share, with a total value of $255,450.00. Following the acquisition, the executive directly owned 139,000 shares of the company’s stock, valued at approximately $546,270. This trade represents a 87.84% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Over the last ninety days, insiders have bought 83,200 shares of company stock worth $322,282. 4.08% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Sintx Technologies

A number of large investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its holdings in Sintx Technologies by 33.5% during the 2nd quarter. Geode Capital Management LLC now owns 15,339 shares of the company’s stock valued at $49,000 after purchasing an additional 3,848 shares during the last quarter. Veracity Capital LLC lifted its stake in Sintx Technologies by 10.3% in the third quarter. Veracity Capital LLC now owns 79,928 shares of the company’s stock worth $327,000 after purchasing an additional 7,464 shares during the last quarter. Finally, Virtus Wealth Solutions LLC bought a new position in shares of Sintx Technologies during the third quarter valued at approximately $388,000. 18.38% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on SINT shares. Ascendiant Capital Markets decreased their target price on Sintx Technologies from $25.00 to $16.00 and set a “buy” rating on the stock in a research report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sintx Technologies in a report on Wednesday, October 8th. Finally, Wall Street Zen downgraded Sintx Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $16.00.

Sintx Technologies Stock Performance

SINT stock traded up $0.07 during midday trading on Monday, reaching $3.74. 7,489 shares of the company traded hands, compared to its average volume of 39,489. The firm has a market capitalization of $13.76 million, a price-to-earnings ratio of -0.66 and a beta of 0.65. Sintx Technologies has a 52-week low of $1.71 and a 52-week high of $7.36. The business has a 50 day moving average of $3.67 and a 200-day moving average of $3.63.

Sintx Technologies (NASDAQ:SINT) last released its earnings results on Wednesday, November 12th. The company reported ($3.46) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($2.91). Sintx Technologies had a negative net margin of 775.12% and a negative return on equity of 218.25%. The company had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.20 million.

About Sintx Technologies

Sintx Technologies, Inc (NASDAQ: SINT) is a medical materials company specializing in the development and manufacture of silicon nitride-based biomaterials for surgical and implantable medical devices. Its proprietary silicon nitride ceramic combines mechanical strength, biocompatibility and intrinsic antimicrobial properties, positioning it as an alternative to traditional metal and polymer implant materials. Sintx’s primary focus is on applications in spinal fusion, trauma fixation and dental implantology, where device performance and long-term biological response are critical.

The company’s core product offerings include silicon nitride powders for advanced implant fabrication and finished implantable components designed for interbody spinal fusion cages, spinal fixation hardware and trauma plates and screws.